The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The companies clash over survival curve similarities – and differences.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Petosemtamab's phase 2 data in this setting should come by the year end.
After ZW171's exit, ZW251 enters the clinic.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
